Nirsevimab for RSV Prevention in India: Economic Viability and Implementation Pathways for National Introduction: A Review
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in Indian infants, with an estimated 800,000–1.2 million annual hospitalizations. Nirsevimab, a long-acting monoclonal antibody providing single-dose seasonal protection, has recently become available in India but remains cost-prohibitive for...